On Oct. 12, 2010, Bristol-Myers Squibb Company announced it had completed its acquisition of ZymoGenetics. Bristol-Myers Squibb initiated on September 10, 2010, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share. The transaction had an aggregate purchase price of $885 million. As a result of the transaction, ZymoGenetics became a wholly-owned subsidiary of Bristol-Myers Squibb.

Based on information provided by the Depositary to Parent, as of the expiration of the Offer, approximately 82,605,529 shares were validly tendered and not validly withdrawn prior to the expiration of the Offer, representing approximately 94.9% of the ZymoGenetics shares outstanding. As of the close of business on October 11, 2010, approximately 981,756 shares remained subject to guaranteed delivery procedures.

Bristol-Myers Squibb intends to delist and de-register ZymoGenetics common stock as promptly as practicable following the effective time of the merger.